Ekso Bionics Holdings, Inc. reported a significant decline in its financial performance for the fiscal year ending December 31, 2025, with total revenue of $12.8 million, a decrease of 29% from $17.9 million in 2024. The company's gross profit also fell by 28% to $6.8 million, maintaining a gross margin of approximately 53%. The decline in revenue was primarily attributed to reduced sales of Enterprise Health devices in the Europe, Middle East, and Africa (EMEA) region, although there was a noted increase in Personal Health device sales in the Americas. The company recorded a net loss of $11.7 million, slightly higher than the $11.3 million loss reported in the previous year.
In terms of operational changes, Ekso Bionics has been actively pursuing strategic initiatives, including the marketing of the MediTouch BalanceTutor, which is expected to begin distribution in early 2026. The company has also made progress in its Personal Health market, particularly following the approval of a Medicare reimbursement rate of approximately $91,000 for the Ekso Indego Personal device, effective April 1, 2024. This development is anticipated to enhance demand for the device among individuals with spinal cord injuries, as approximately 57% of this population is enrolled in Medicare or Medicaid within five years post-injury.
The company’s workforce consisted of 50 full-time employees as of February 20, 2026, with no employees covered by collective bargaining agreements. Ekso Bionics has also been focusing on refining its reimbursement submission processes, which have seen improvements in the speed of claims approvals. As of December 31, 2025, the company had over 50 individuals who qualify for potential reimbursement, with expectations for claims to be submitted in the coming year.
Looking ahead, Ekso Bionics is navigating a challenging financial landscape, with substantial doubt about its ability to continue as a going concern due to ongoing operating losses and cash flow deficits. The company is actively seeking additional financing to support its operations, with plans to raise funds through various means, including equity offerings and potential strategic partnerships. The anticipated business combination with Applied Digital Corporation's cloud computing business, expected to close in the second quarter of 2026, is also a critical component of the company's strategy to enhance its market position and financial stability.
About EKSO BIONICS HOLDINGS, INC.
Ekso Bionics Holdings, Inc. designs and markets exoskeleton devices that enhance human mobility, strength, and endurance. Its core products include wearable robotic exoskeletons for medical rehabilitation and personal mobility, serving healthcare providers, veterans, and individuals with disabilities. The company operates globally, focusing on regulatory compliance, clinical validation, and competitive innovation in the medical and industrial robotics sectors.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.